Skip to main content
    C

    Champions Oncology Inc (CSBR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    -0.14 (-3.08%)

    Market Cap: $65.49M

    Last updated: Nov 17, 2026 at 10:50 AM ET

    Champions Oncology Inc (CSBR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Champions Oncology are Cardiff Oncology (CRDF), Oncolytics Biotech (ONCY) and NeOnc Technologies Holdings, Inc. Common Stock (NTHI). By market cap, Champions Oncology ranks 8th of the 13 companies on this page; NeOnc Technologies Holdings, Inc. Common Stock (NTHI) is the largest at $141.66M.

    Peer Comparison

    CSBR's revenue growth of 8.8% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Champions Oncology (CSBR)$65.49MN/A1.0x-1.9%N/A8.8%0.00%
    Cardiff Oncology Inc (CRDF)$56.49MN/A115.5x0.0%N/A-14.1%0.00%
    Oncolytics Biotech Inc (ONCY)$48.51MN/AN/A0.0%N/A0.0%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    Anixa Biosciences Inc (ANIX)$91.08MN/AN/A0.0%N/A0.0%0.00%
    Coherus BioSciences Inc (CHRS)$81.21MN/A1.5x-253.4%-144.8%23.4%0.00%
    OnKure Therapeutics, Inc. (OKUR)$108.33MN/AN/A0.0%N/A0.0%0.00%
    Nkarta Inc (NKTX)$85.23MN/AN/A0.0%N/A0.0%0.00%
    RenovoRx Inc (RNXT)$50.18MN/A16.6x0.0%N/A300.8%0.00%
    Genelux Corporation Common Stock (GNLX)$84.38MN/AN/A0.0%N/A-95.3%0.00%
    Actinium Pharmaceuticals Inc (ATNM)$51.56M4.1x1.3x32.2%N/A-100.0%0.00%
    Cognition Therapeutics Inc (CGTX)$64.65MN/AN/A0.0%N/A0.0%0.00%
    Corbus Pharmaceuticals Holding (CRBP)$69.86MN/A13.9x0.0%-106.7%-100.0%0.00%
    Peer median$75.53M4.1x13.9x0.0%-125.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Champions Oncology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Cardiff Oncology Inc (CRDF)
    Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer.
    CRDF competitors
    Oncolytics Biotech Inc (ONCY)
    Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer.
    ONCY competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    Anixa Biosciences Inc (ANIX)
    Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
    ANIX competitors
    Coherus BioSciences Inc (CHRS)
    Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States.
    CHRS competitors
    OnKure Therapeutics, Inc. (OKUR)
    OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
    OKUR competitors
    Nkarta Inc (NKTX)
    Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer.
    NKTX competitors
    RenovoRx Inc (RNXT)
    RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.
    RNXT competitors
    Genelux Corporation Common Stock (GNLX)
    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering...
    GNLX competitors
    Actinium Pharmaceuticals Inc (ATNM)
    Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation...
    ATNM competitors
    Cognition Therapeutics Inc (CGTX)
    Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting...
    CGTX competitors
    Corbus Pharmaceuticals Holding (CRBP)
    Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target...
    CRBP competitors

    Frequently Asked Questions About CSBR

    Who are Champions Oncology's main competitors?

    The companies most similar to Champions Oncology include Cardiff Oncology (CRDF), Oncolytics Biotech (ONCY), NeOnc Technologies Holdings, Inc. Common Stock (NTHI), Anixa Biosciences (ANIX) and Coherus BioSciences (CHRS), listed from the closest match.

    Who is Champions Oncology's biggest competitor?

    NeOnc Technologies Holdings, Inc. Common Stock (NTHI) is the largest of the similar companies at $141.66M; Cardiff Oncology (CRDF) is the closest match by business profile, size, sector and industry.

    How does CSBR stock compare with its competitors?

    CSBR's P/S is 1.0x against a peer median of 13.9x; its net margin is -1.9% against a peer median of 0.0%.

    Which of Champions Oncology's competitors pays a higher dividend?

    Champions Oncology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Champions Oncology bigger than its competitors?

    No. Champions Oncology is 8th by market cap among the 13 companies on this page; the largest is NeOnc Technologies Holdings, Inc. Common Stock (NTHI) at $141.66M.